A citation-based method for searching scientific literature

Steven R Goldsmith. Cleve Clin J Med 2006
Times Cited: 32







List of co-cited articles
326 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Hormones and hemodynamics in heart failure.
R W Schrier, W T Abraham. N Engl J Med 1999
827
21

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Marvin A Konstam, Mihai Gheorghiade, John C Burnett, Liliana Grinfeld, Aldo P Maggioni, Karl Swedberg, James E Udelson, Faiez Zannad, Thomas Cook, John Ouyang,[...]. JAMA 2007
21

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Mihai Gheorghiade, Wendy A Gattis, Christopher M O'Connor, Kirkwood F Adams, Uri Elkayam, Alejandro Barbagelata, Jalal K Ghali, Raymond L Benza, Frank A McGrew, Marc Klapholz,[...]. JAMA 2004
517
21

Vasopressin: a new target for the treatment of heart failure.
Craig R Lee, Michael L Watkins, J Herbert Patterson, Wendy Gattis, Christopher M O'connor, Mihai Gheorghiade, Kirkwood F Adams. Am Heart J 2003
156
21

Increased plasma arginine vasopressin levels in patients with congestive heart failure.
S R Goldsmith, G S Francis, A W Cowley, T B Levine, J N Cohn. J Am Coll Cardiol 1983
434
21





Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
James E Udelson, Frank A McGrew, Enrique Flores, Hassan Ibrahim, Stewart Katz, Gregory Koshkarian, Terrence O'Brien, Marvin W Kronenberg, Christopher Zimmer, Cesare Orlandi,[...]. J Am Coll Cardiol 2007
126
15

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Mihai Gheorghiade, Marvin A Konstam, John C Burnett, Liliana Grinfeld, Aldo P Maggioni, Karl Swedberg, James E Udelson, Faiez Zannad, Thomas Cook, John Ouyang,[...]. JAMA 2007
620
15


Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.
J E Udelson, W B Smith, G H Hendrix, C A Painchaud, M Ghazzi, I Thomas, J K Ghali, P Selaru, F Chanoine, M L Pressler,[...]. Circulation 2001
269
15

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.
Liviu Klein, Christopher M O'Connor, Jeffrey D Leimberger, Wendy Gattis-Stough, Ileana L Piña, G Michael Felker, Kirkwood F Adams, Robert M Califf, Mihai Gheorghiade. Circulation 2005
364
12


Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor.
Y Nakamura, T Haneda, J Osaki, S Miyata, K Kikuchi. Eur J Pharmacol 2000
81
12

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Mihai Gheorghiade, Imran Niazi, John Ouyang, Frank Czerwiec, Jun-ichi Kambayashi, Manuela Zampino, Cesare Orlandi. Circulation 2003
343
12

Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
Stephanie Neuhold, Martin Huelsmann, Guido Strunk, Brigitte Stoiser, Joachim Struck, Nils G Morgenthaler, Andreas Bergmann, Deddo Moertl, Rudolf Berger, Richard Pacher. J Am Coll Cardiol 2008
174
12

Adverse consequences of high sympathetic nervous activity in the failing human heart.
D M Kaye, J Lefkovits, G L Jennings, P Bergin, A Broughton, M D Esler. J Am Coll Cardiol 1995
530
12

Evidence for a vasopressin system in the rat heart.
H Hupf, D Grimm, G A Riegger, H Schunkert. Circ Res 1999
81
12

Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling.
Xue Li, Tung O Chan, Valerie Myers, Ibrul Chowdhury, Xue-Qian Zhang, Jianliang Song, Jin Zhang, Jocelyn Andrel, Hajime Funakoshi, Jeffrey Robbins,[...]. Circulation 2011
41
12

Angiotensin II induces catecholamine release by direct ganglionic excitation.
Andreas Dendorfer, Alexandra Thornagel, Walter Raasch, Olaf Grisk, Klaus Tempel, Peter Dominiak. Hypertension 2002
77
12

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
12

Science review: Vasopressin and the cardiovascular system part 1--receptor physiology.
Cheryl L Holmes, Donald W Landry, John T Granton. Crit Care 2003
208
9


Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
Alain Soupart, Peter Gross, Jean-Jacques Legros, Sándor Alföldi, Djillali Annane, Hassan M Heshmati, Guy Decaux. Clin J Am Soc Nephrol 2006
97
9


The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions.
Akito Tanoue, Shuji Ito, Kenji Honda, Sayuri Oshikawa, Yoko Kitagawa, Taka-Aki Koshimizu, Toyoki Mori, Gozoh Tsujimoto. J Clin Invest 2004
172
9

Hyponatremia and vasopressin antagonism in congestive heart failure.
Siva Kumar, Sharon Rubin, Paul J Mather, David J Whellan. Clin Cardiol 2007
20
15

Phospholamban: a crucial regulator of cardiac contractility.
David H MacLennan, Evangelia G Kranias. Nat Rev Mol Cell Biol 2003
735
9

Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.
Mihai Gheorghiade, Joseph S Rossi, William Cotts, David D Shin, Anne S Hellkamp, Ileana L Piña, Gregg C Fonarow, Teresa DeMarco, Daniel F Pauly, Joseph Rogers,[...]. Arch Intern Med 2007
258
9

Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.
Nils G Morgenthaler, Joachim Struck, Christine Alonso, Andreas Bergmann. Clin Chem 2006
763
9


Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure.
V L Szatalowicz, P E Arnold, C Chaimovitz, D Bichet, T Berl, R W Schrier. N Engl J Med 1981
367
9

The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists.
M Thibonnier, P Coles, A Thibonnier, M Shoham. Annu Rev Pharmacol Toxicol 2001
114
9

Hyponatremia in patients with heart failure.
Leonardo De Luca, Liviu Klein, James E Udelson, Cesare Orlandi, Gennaro Sardella, Francesco Fedele, Mihai Gheorghiade. Am J Cardiol 2005
61
9

Neural control of renal function in edema-forming states.
G F DiBona, P J Herman, L L Sawin. Am J Physiol 1988
85
9

Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Jalal K Ghali, Michael J Koren, James R Taylor, Esther Brooks-Asplund, Kaisheng Fan, Walker A Long, Neila Smith. J Clin Endocrinol Metab 2006
140
9

Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
David Zeltser, Steven Rosansky, Hannes van Rensburg, Joseph G Verbalis, Neila Smith. Am J Nephrol 2007
142
9

Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.
Douglas S Lee, Peter C Austin, Jean L Rouleau, Peter P Liu, David Naimark, Jack V Tu. JAMA 2003
9

Hyponatremia.
H J Adrogué, N E Madias. N Engl J Med 2000
9

Upregulation of aquaporin-2 water channel expression in chronic heart failure rat.
D L Xu, P Y Martin, M Ohara, J St John, T Pattison, X Meng, K Morris, J K Kim, R W Schrier. J Clin Invest 1997
231
9


Hyponatremia in congestive heart failure.
Ron M Oren. Am J Cardiol 2005
102
9

Physiology and pathophysiology of renal aquaporins.
S Nielsen, T H Kwon, B M Christensen, D Promeneur, J Frøkiaer, D Marples. J Am Soc Nephrol 1999
234
9

Clinical practice. The syndrome of inappropriate antidiuresis.
David H Ellison, Tomas Berl. N Engl J Med 2007
548
9

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Robert W Schrier, Peter Gross, Mihai Gheorghiade, Tomas Berl, Joseph G Verbalis, Frank S Czerwiec, Cesare Orlandi. N Engl J Med 2006
789
9

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.
J N Cohn, T B Levine, M T Olivari, V Garberg, D Lura, G S Francis, A B Simon, T Rector. N Engl J Med 1984
9

Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure.
Arash Aghel, Kevin Shrestha, Wilfried Mullens, Allen Borowski, W H Wilson Tang. J Card Fail 2010
170
9

Biomarkers in heart failure.
Eugene Braunwald. N Engl J Med 2008
892
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.